I'm not sure I can give you an exact figure on the percentage of the global market. Right now, I would say it's probably fairly small in the lutetium-177 area. In the alpha therapies that I mentioned, which is the actinium, we're really just on the cusp of starting to get companies involved in this. Right now we are still very much in pre-clinical trials, so when we look at the actual amount of material that's out there, as I said, it's very small.
One of the issues we have in actually being able to advance further development of these treatments is getting enough material so that the industry or the clinicians can be ready to use it.
I know I have just a couple of seconds here. We believe that Canada has the opportunity—not only with Bruce Power and the reactors at Bruce Power and OPG, but also with CNL—to take over the radioisotope leadership in the world. I think the talent is here, the production capabilities are here and the urgency is here as well.